Cargando…
Evaluation and management of platelet transfusion refractoriness
Platelet transfusion refractoriness (PTR), in which platelet counts do not increase after transfusion, occurs in many patients receiving platelet transfusions. PTR is a clinical condition that can harm patients. The causes of PTR can be divided into two types: immune and non-immune. Most cases of PT...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057673/ https://www.ncbi.nlm.nih.gov/pubmed/35483919 http://dx.doi.org/10.5045/br.2022.2021229 |
_version_ | 1784697951402065920 |
---|---|
author | Youk, Hee-Jeong Hwang, Sang-Hyun Oh, Heung-Bum Ko, Dae-Hyun |
author_facet | Youk, Hee-Jeong Hwang, Sang-Hyun Oh, Heung-Bum Ko, Dae-Hyun |
author_sort | Youk, Hee-Jeong |
collection | PubMed |
description | Platelet transfusion refractoriness (PTR), in which platelet counts do not increase after transfusion, occurs in many patients receiving platelet transfusions. PTR is a clinical condition that can harm patients. The causes of PTR can be divided into two types: immune and non-immune. Most cases of PTR are non-immune. Among immune causes, the most common is human leukocyte antigen (HLA) class I molecules. PTR caused by anti-HLA antibodies is usually managed by transfusing HLA-matched platelets. Therefore, it is important, especially for hemato-oncologists who frequently perform transfusion, to accurately diagnose whether the cause of platelet transfusion failure is alloimmune or non-immunological when determining the treatment direction for the patient. In this review, we discuss the definitions, causes, countermeasures, and prevention methods of PTR. |
format | Online Article Text |
id | pubmed-9057673 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis |
record_format | MEDLINE/PubMed |
spelling | pubmed-90576732022-05-10 Evaluation and management of platelet transfusion refractoriness Youk, Hee-Jeong Hwang, Sang-Hyun Oh, Heung-Bum Ko, Dae-Hyun Blood Res Review Article Platelet transfusion refractoriness (PTR), in which platelet counts do not increase after transfusion, occurs in many patients receiving platelet transfusions. PTR is a clinical condition that can harm patients. The causes of PTR can be divided into two types: immune and non-immune. Most cases of PTR are non-immune. Among immune causes, the most common is human leukocyte antigen (HLA) class I molecules. PTR caused by anti-HLA antibodies is usually managed by transfusing HLA-matched platelets. Therefore, it is important, especially for hemato-oncologists who frequently perform transfusion, to accurately diagnose whether the cause of platelet transfusion failure is alloimmune or non-immunological when determining the treatment direction for the patient. In this review, we discuss the definitions, causes, countermeasures, and prevention methods of PTR. Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2022-04-30 2022-04-30 /pmc/articles/PMC9057673/ /pubmed/35483919 http://dx.doi.org/10.5045/br.2022.2021229 Text en © 2022 Korean Society of Hematology https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Youk, Hee-Jeong Hwang, Sang-Hyun Oh, Heung-Bum Ko, Dae-Hyun Evaluation and management of platelet transfusion refractoriness |
title | Evaluation and management of platelet transfusion refractoriness |
title_full | Evaluation and management of platelet transfusion refractoriness |
title_fullStr | Evaluation and management of platelet transfusion refractoriness |
title_full_unstemmed | Evaluation and management of platelet transfusion refractoriness |
title_short | Evaluation and management of platelet transfusion refractoriness |
title_sort | evaluation and management of platelet transfusion refractoriness |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057673/ https://www.ncbi.nlm.nih.gov/pubmed/35483919 http://dx.doi.org/10.5045/br.2022.2021229 |
work_keys_str_mv | AT youkheejeong evaluationandmanagementofplatelettransfusionrefractoriness AT hwangsanghyun evaluationandmanagementofplatelettransfusionrefractoriness AT ohheungbum evaluationandmanagementofplatelettransfusionrefractoriness AT kodaehyun evaluationandmanagementofplatelettransfusionrefractoriness |